| dc.contributor.author | Matthias Schneider | |
| dc.contributor.author | Ralph Brinks | |
| dc.contributor.author | Johanna Mucke | |
| dc.contributor.author | Oliver Kuss | |
| dc.contributor.author | Sabine Schanze | |
| dc.contributor.other | 2 Policlinic and Hiller Research Unit for Rheumatology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany | |
| dc.contributor.other | 1 Rheumatology and Hiller Research Unit, Heinrich-Heine-University Düsseldorf, Medical Faculty, Düsseldorf, Germany | |
| dc.contributor.other | Policlinic and Hiller Research Unit, Heinrich Heine University Düsseldorf, Dusseldorf, Nordrhein-Westfalen, Germany | |
| dc.contributor.other | German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich Heine University Düsseldorf, Düsseldorf, Germany | |
| dc.contributor.other | German Lupus Self-Help Community, Wuppertal, Germany | |
| dc.date.accessioned | 2025-10-09T05:20:17Z | |
| dc.date.available | 2025-10-09T05:20:17Z | |
| dc.date.issued | 01-May-2021 | |
| dc.identifier.uri | https://lupus.bmj.com/content/8/1/e000516.full | |
| dc.identifier.uri | http://digilib.fisipol.ugm.ac.id/repo/handle/15717717/40972 | |
| dc.description.abstract | Introduction As chronic systemic autoimmune disease, which can affect every organ, SLE is creating significant burden and increased mortality. Despite better outcomes over the past decades by optimising standard of care, new interventions are needed for further improvements. Changing strategy to ‘treat-to-target’ (T2T) may be a promising concept proven successful in other chronic diseases.Methods and analysis In this cluster-randomised trial, SLE centres will be assigned 1:1:1 to standard of care (SoC), remission (no clinical disease activity+prednisolone ≤5 mg/day+Physician Global Assessment (PGA 0–3) <0.5±immunomodulatory treatment) or and Lupus Low Disease Activity State (LLDAS, low disease activity+prednisolone ≤7.5 mg/day+PGA ≤1+no new disease activity). Per arm, 424 patients will be included. Intervention centres receive a standardised training on T2T and shared decision-making (SDM). In intervention centres, patients not in target enter a phase of tight control with six weekly visits and treatment adjustments (at least four visits) or until the target is reached and maintained. Patients in target are reassessed every 12 weeks. In case of flare, they can enter tight control based on SDM. In the SoC arm, patients receive their usual three to six monthly controls and treatment adjustments according to the physician’s discretion. Study duration is 120 weeks using change in damage and health-related quality of life (HRQoL) as major outcomes. The primary endpoint will be damage accrual at 120 weeks as measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index and will by analysed by a mixed model.Conclusions This is the first trial to assess if the implementation of a T2T concept in clinical care minimises damage accrual and improves HRQoL in patients with SLE. Comparison of remission and LLDAS will help to identify the target with the best benefit–risk ratio concerning attainability, adverse events and damage. The emphasis on SDM will strengthen patient autonomy and will improve both their satisfaction and medical condition. | |
| dc.language.iso | EN | |
| dc.publisher | BMJ Publishing Group | |
| dc.subject.lcc | Immunologic diseases. Allergy | |
| dc.title | LUPUS-BEST—treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial | |
| dc.type | Article | |
| dc.description.doi | 10.1136/lupus-2021-000516 | |
| dc.title.journal | Lupus Science and Medicine | |
| dc.identifier.e-issn | 2053-8790 | |
| dc.identifier.oai | oai:doaj.org/journal:0f186ea4cdff408e899ab7afdc2135b4 | |
| dc.journal.info | Volume 8, Issue 1 | |
